|
Sonnet Biotherapeutics Holdings, Inc. (SONN) DCF -Bewertung
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Sonnet BioTherapeutics Holdings, Inc. (SONN) Bundle
Verbessern Sie Ihre Anlagestrategien mit dem DCF -Taschenrechner des Sonnet Biotherapeutics Holdings, Inc. (SONN)! Tauchen Sie in reale Finanzdaten ein, passen Sie Wachstumsprojektionen und -kosten an und beobachten Sie, wie sich diese Veränderungen sofort auf den inneren Wert von Sonnet Biotherapeutics auswirken.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .5 | .3 | .1 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | -27.64 | -57.76 | -87.4 | -43.2 | -43.2 | -43.2 | -43.2 | -43.2 |
| EBITDA | -24.2 | -25.0 | -29.6 | -18.7 | -11.8 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | -5167.69 | -8451.69 | -12663.22 | -63617.91 | -60 | -60 | -60 | -60 | -60 |
| Depreciation | .1 | .1 | .1 | .1 | .0 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 19.68 | 26.65 | 51.25 | 0 | 39.52 | 39.52 | 39.52 | 39.52 | 39.52 |
| EBIT | -24.3 | -25.1 | -29.7 | -18.8 | -11.8 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | -5187.36 | -8478.34 | -12714.47 | -63617.91 | -60 | -60 | -60 | -60 | -60 |
| Total Cash | 7.3 | 27.6 | 3.1 | 2.3 | .1 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .8 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 0 | 0 | 532.17 | 0 | 40 | 40 | 40 | 40 | 40 |
| Inventories | .0 | .0 | -.7 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 0 | -204.98 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Payable | 2.1 | 3.8 | 4.8 | 2.2 | 2.2 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 781.86 | 1358.03 | 1489.8 | 11722.41 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | -.1 | .0 | -.9 | -.4 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | -0.74913 | -256.18 | -299.89 | 0 | -40.15 | -40.15 | -40.15 | -40.15 | -40.15 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -31.1 | -25.1 | -29.7 | -18.8 | -11.8 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -29.1 | -23.3 | -28.8 | -23.2 | -11.1 | -2.2 | .0 | .0 | .0 | .0 |
| WACC, % | 8.32 | 8.32 | 8.32 | 8.32 | 8.32 | 8.32 | 8.32 | 8.32 | 8.32 | 8.32 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -2.0 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -2 | |||||||||
| Net Debt | 0 | |||||||||
| Equity Value | -2 | |||||||||
| Diluted Shares Outstanding, MM | 1 | |||||||||
| Equity Value Per Share | -3.08 |
What You Will Get
- Editable Forecast Inputs: Easily modify key assumptions (growth %, margins, WACC) to explore various scenarios.
- Real-World Data: Sonnet BioTherapeutics Holdings, Inc. (SONN) financial data pre-loaded to facilitate your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value automatically.
- Customizable and Professional: A refined Excel model tailored to meet your valuation requirements.
- Built for Analysts and Investors: Perfect for evaluating projections, confirming strategies, and enhancing efficiency.
Key Features
- Comprehensive Biotech Data: Gain access to accurate pre-loaded historical data and future projections specific to Sonnet BioTherapeutics Holdings, Inc. (SONN).
- Tailored Forecast Assumptions: Modify highlighted cells for key metrics like WACC, growth rates, and profit margins.
- Real-Time Calculations: Instant updates to DCF, Net Present Value (NPV), and cash flow assessments.
- User-Friendly Dashboard: Clear and concise charts and summaries to help visualize your valuation outcomes.
- Suitable for All Levels: An accessible, intuitive format designed for investors, CFOs, and consultants alike.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Sonnet BioTherapeutics data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Sonnet BioTherapeutics' intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose This Calculator for Sonnet BioTherapeutics Holdings, Inc. (SONN)?
- Accurate Data: Utilize real Sonnet BioTherapeutics financials for dependable valuation assessments.
- Customizable: Tailor essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Pre-configured calculations save you the hassle of starting from the ground up.
- Professional-Grade Tool: Crafted for investors, analysts, and consultants in the biotech sector.
- User-Friendly: Easy-to-navigate design and comprehensive instructions make it accessible for all users.
Who Should Use This Product?
- Professional Investors: Develop comprehensive and accurate valuation models for portfolio assessment of Sonnet BioTherapeutics Holdings, Inc. (SONN).
- Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decisions within their organizations.
- Consultants and Advisors: Deliver precise valuation insights to clients interested in Sonnet BioTherapeutics Holdings, Inc. (SONN).
- Students and Educators: Utilize real-world data to enhance learning and practice in financial modeling.
- Biotech Enthusiasts: Gain insights into how biotech firms like Sonnet BioTherapeutics Holdings, Inc. (SONN) are valued in the financial markets.
What the Sonnet BioTherapeutics Template Contains
- Comprehensive DCF Model: Editable template featuring in-depth valuation calculations tailored for Sonnet BioTherapeutics.
- Real-World Data: Sonnet BioTherapeutics Holdings, Inc. (SONN) historical and projected financials preloaded for thorough analysis.
- Customizable Parameters: Modify WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights into performance.
- Key Ratios: Integrated analysis of profitability, efficiency, and leverage specific to Sonnet BioTherapeutics.
- Dashboard with Visual Outputs: Engaging charts and tables that present clear, actionable results for decision-making.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.